Clinical Trials in Miami

Showing 7421-7440 of 11,431 trials

Biomarkers for Post-Transplant Lymphoproliferative Disorders in Children

NCT02182986

Solid organ transplantation is an important therapeutic option for children with a variety of end stage diseases. However, the same immunosuppressive medications that are required to prevent the child's immune system from attacking and rejecting the transplanted organ can predispose these individuals to developing a very serious cancer that is linked to Epstein-Barr virus (EBV).

Heart TransplantSmall Intestine TransplantKidney Transplant+3 more

National Institute of Allergy and Infectious Diseases (NIAID)944 participantsStarted Aug 2014

Los Angeles, California, United States • Stanford, California, United States • Washington D.C., District of Columbia, United States +4 more locations

No Longer Available< 1 mile

Expanded Access Program to Provide Treatment With Pitolisant to Adult Patients in the U.S. With Excessive Daytime Sleepiness Associated With Narcolepsy With or Without Cataplexy

NCT03433131

This EAP will be open to provide access to treatment with pitolisant while a U.S. New Drug Application (NDA) is being prepared and submitted for review for marketing approval. This program will be open to adult patients in the U.S. with Excessive Daytime Sleepiness (EDS) associated with narcolepsy, with or without cataplexy. Pitolisant will be made available through treating physicians participating in the program.

Narcolepsy Without CataplexyNarcolepsy With Cataplexy

Harmony Biosciences Management, Inc.

Birmingham, Alabama, United States • Cullman, Alabama, United States • Phoenix, Arizona, United States +68 more locations

Biomarkers for Post-Transplant Lymphoproliferative Disorders in Children

Expanded Access Program to Provide Treatment With Pitolisant to Adult Patients in the U.S. With Excessive Daytime Sleepiness Associated With Narcolepsy With or Without Cataplexy

Find Trials by Condition in Miami

An Extension Study to Evaluate the Long-Term Safety and Tolerability of Ubrogepant in the Treatment of Migraine

Positive Imaging Study for Distant Metastases in Patients With Castration-Resistant Prostate Cancer

A Dose-Range Finding Study for ALX-0061 Combination Therapy in Subjects With Rheumatoid Arthritis

A Safety Extension Study to Evaluate the Safety and Tolerability of Benralizumab (MEDI-563) in Asthmatic Adults and Adolescents on Inhaled Corticosteroid Plus LABA

Long-term Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy in Patients With Major Depressive Disorder

A Study to Evaluate the Effect of Dapagliflozin With and Without Saxagliptin on Albuminuria, and to Investigate the Effect of Dapagliflozin and Saxagliptin on HbA1c in Patients With Type 2 Diabetes and CKD

Efficacy and Safety of Etelcalcetide (AMG 416) in the Treatment of Secondary Hyperparathyroidism (SHPT) in Patients With Chronic Kidney Disease (CKD) on Hemodialysis

A Phase IIb Study for ALX-0061 Monotherapy in Subjects With Rheumatoid Arthritis

A Study to Evaluate the Safety of Rituximab Retreatment in Subjects With Systemic Lupus Erythematosus

Expanded Access /Compassionate Use Protocol For Relapsed Or Refractory CD33 Positive AML Patients In The USA Without Access To Comparable Or Alternative Therapy

A Study of the Effect of XmAb®5871 in Patients With Systemic Lupus Erythematosus

A Study of Disease Progression in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration

BOTOX® Open-Label Treatment in Pediatric Lower Limb Spasticity

Comparing Complete Remission After Treatment With Selumetinib/Placebo in Patient With Differentiated Thyroid Cancer

A Study of Venetoclax Plus Lenalidomide and Dexamethasone for the Treatment of Newly Diagnosed t(11;14)-Positive Multiple Myeloma in Subjects Who Are Ineligible for High-Dose Therapy

Pivotal Study in VAP Suspected or Confirmed to be Due to Pseudomonas Aeruginosa

Health and Wellness in Healthcare Providers Post-disaster

A Study to Assess All-Cause Mortality and Cardiovascular Morbidity in Participants With Chronic Kidney Disease (CKD) on Dialysis and Those Not on Renal Replacement Therapy Receiving Methoxy Polyethylene Glycol-Epoetin Beta (Mircera) or Reference Erythropoietin Stimulating Agents (ESAs)